Replies to post #101103 on Elite Pharmaceuticals Inc (ELTP)

[Couch]

The value accretion curve in pharmaceuticals is very high, and what that means is that the difference in value between licensing a product that has completed Phase I versus licensing a product that has completed Phase III or has an NDA already filed, is logarithmic. The value of a product accretes very rapidly once it gets into human clinical trials.

We have two opioid abuse deterrent products, ELI-200 and ELI-201, in human trials and an additional five abuse deterrent formulations under active development.